衡量医药创新回报（英）-32页

下载本文档

阅读 1615
下载 28
格式 pdf
大小 3.82 MB
约31页
2024-08-22
收藏
评论
点赞(0)
海报
举报

/31

April2024UnleashAI’spotentialMeasuringthereturnfrompharmaceuticalinnovation–14theditionForeword1Executivesummary2Measuringthereturnfrom4pharmaceuticalinnovationRealisingefficiencyopportunities8Optimisingthevalueofpipelines14Strategiestoimproveproductivity18KeyquestionsforanoptimumR&Dstrategy24Endnotes25Contacts27ContentsForewordWelcometoUnleashAI’spotential,Deloitte’sfourteenthannualreportinourMeasuringthereturnfrompharmaceuticalinnovationseries.Ourreportexplorestheperformanceofthebiopharmaceutical(biopharma)industryanditsabilitytogeneratereturnsfrominvestmentininnovativeproductsinthedevelopmentpipeline.ThecurrentbiopharmaR&Doperatingmodelfacesseveralseriouschallenges,includingongoingregulatorychanges,lossofexclusivityofanunprecedentednumberofhigh-valueassets,andtherapidpaceofscientificandtechnologicaladvancements.However,advancesindigitalisationandartificialintelligence(AI)presentnewopportunitiestoimproveR&Dproductivity,pavingthewayforaneweraofinnovationandacceleratingpatientaccesstonewtherapies.Asalways,ourreportexplorestheindustry’sperformance,thechangingcharacteristicsofthelate-stageportfoliosandtheopportunitiesforbiopharmacompaniestoimprovecapitalreturns.Between2010and2023,ourreportserieshasprovidedinsightsintotheproductivityofbiopharmaR&D.In2010,weanalysedtheexpectedreturnoninvestmentfromthelate-st...

1、当您付费下载文档后，您只拥有了使用权限，并不意味着购买了版权，文档只能用于自身使用，不得用于其他商业用途（如 [转卖]进行直接盈利或[编辑后售卖]进行间接盈利）。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。
3、如文档内容存在违规，或者侵犯商业秘密、侵犯著作权等，请点击“违规举报”。

碎片内容